Back to search
FDAFDA · Food and drugs·Recall number D-0539-2025

EVENITY, (romosozumab -aqqg) injection, 105mg/1.17 mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-880-02.

Published July 30, 2025 · Recall initiated: April 21, 2025

Summary

FDA records drug Class II recall D-0539-2025, published July 30, 2025 and initiated April 21, 2025. Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office; Status: Ongoing; Reported quantity: 2 Pre-filled syringes; Lot: Lot: 1178382, Expiration date: 3/31/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations; potential temperature excursions due to transit delays

What to do

Voluntary: Firm initiated · Letter

Get an email if EVENITY has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
EVENITY
Manufacturer
Mckesson Medical-Surgical Inc. Corporate Office
Distributor
Within the U.S - OH, VA, FL.
Lot
Lot: 1178382, Expiration date: 3/31/2027
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was EVENITY, (romosozumab -aqqg) injection, 105mg/1.17 mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-880-02. recalled?

Yes. FDA published recall D-0539-2025 on July 30, 2025. Reported hazard: CGMP Deviations; potential temperature excursions due to transit delays

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: EVENITY.